VeriSim acquires drug discovery company Molomics Biotech

By The Science Advisory Board staff writers

May 12, 2022 -- VeriSim Life has acquired Molomics Biotech, a privately held drug discovery company that uses artificial intelligence (AI) technology to design more efficacious and safer therapeutics for an undisclosed amount.

The Barcelona-based firm incorporates AI with human collective intelligence to determine novel chemical structures with high therapeutic activity on diseases such as Parkinson's and levodopa-induced dyskinesia. The technology will integrate into VeriSim's virtual drug development engine, BioiSim, to further improve the success rates for the discovery, development, and approval of new drugs, the firms said.


Copyright © 2022 scienceboard.net


Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter